Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an exploratory clinical investigation. The objectives of this study are to evaluate
the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the
treatment of psychosis in patients with velocardiofacial syndrome (VCFS).
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.